Commitment to Fight COVID-19
As of May 30, 2022
![[Wastewater-based Epidemiology Surveillance Service]](/content/dam/shionogi/jp/top/index-carousel-19.jpg)
[Wastewater-based Epidemiology Surveillance Service]
By measuring the traces of the virus in wastewater, it is possible to assess, in an unbiased manner, the prevalence of SARS-CoV-2 infections in a community, including asymptomatic individuals who are not tested.
［Mid-term Business plan］
STS2030
~Shionogi Transformation Strategy 2030~
Outline / CEO interview movie
［Innovation］
Drive Innovation
Create innovations beyond the borders of medical / Pharmaceutical fields, unbound from existing concepts, showing every consideration for social issues
［Sustainability］
Grow sustainably as a drug discovery based pharmaceutical company contributing to a more vigorous society through improved healthcare
News
Commitment to Fight COVID-19
Beware of Solicitations, “Phishing” e-mails, and SNS that Fraudulently Use the Name of SHIONOGI
Site Search
Brand Statement
Building innovation platforms to shape the future of healthcare.
SHIONOGI is transforming our business model from a "drug-discovery-oriented pharmaceutical company" to a "healthcare provider" to pursue the health that people truly wish for and deliver new value to society.
